Kymera Therapeutics specializes in targeted protein degradation to develop therapeutics that directly eliminate disease-causing proteins. This approach enables the treatment of a wide range of diseases by addressing the underlying mechanisms of illness, offering new options for patients with unmet medical needs.
Funding
$225M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are caused by specific proteins within the body. Traditional drug development approaches often struggle to effectively target and eliminate these disease-causing proteins, leaving significant unmet needs for patients.
Solution
Kymera Therapeutics is developing a new class of medicines based on targeted protein degradation. This approach directly eliminates disease-causing proteins, rather than just inhibiting their activity. By selectively removing these proteins, Kymera aims to address the underlying mechanisms of disease and offer new treatment options for a wide range of illnesses. Their drug discovery engine is designed to create first-in-class therapeutics with the potential to transform the standard of care.
Target Audience
The primary target audience includes patients with diseases caused by specific proteins and healthcare providers seeking new treatment options.
Features
- Focus on targeted protein degradation as a therapeutic modality
- Development of first-in-class therapeutics
- Addressing a wide range of diseases by targeting underlying protein drivers
- Oral STAT6 degrader (KT-621) in Phase 1 clinical trials for TH2 Immuno-Inflammatory Diseases